Abstract
Warfarin has so far been the only orally effective anticoagulant drug since 40s of 20th century. Despite its undoubted effect it is a problematic drug, especially for the inter-individual variability of its effects, the risk of significant drug, as well as food interactions and narrow therapeutic window.
Development of new, orally active anticoagulants focused on direct thrombin inhibitors and direct factor Xa inhibitors. From the first group dabigatran is already approved for clinical use, i.e. the prevention of thromboembolic events in orthopedic surgery, from the second group rivaroxaban is approved and apixaban is waiting for registration.
Other molecules are still at the stage of clinical evaluation. Clinical evaluations of further important indications are still pending.